New Pathways Identify Novel Drug Targets for the Prevention and Treatment of Alzheimer’s Disease
International Journal of Molecular Sciences · 11.03.2023 · 24 (6) · 5383
DOI: 10.3390/ijms24065383 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 11.03.2023. Verfasst von Botond Penke und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Chemistry, University of Szeged, Dóm Square 8, H-6720 Szeged, Hungary. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 182 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research, Development and Innovation Office, National Research Development and Innovation Office (NKFIH).
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD) is an incurable, progressive neurodegenerative disorder. AD is a complex and multifactorial disease that is responsible for 60–80% of dementia cases. Aging, genetic factors, and epigenetic changes are the main risk factors for AD. Two aggregation-prone proteins play a decisive role in AD pathogenesis: β-amyloid (Aβ) and hyperphosphorylated tau (pTau). Both of them form deposits and diffusible toxic aggregates in the brain. These proteins are the biomarkers of AD. Different hypotheses have tried to explain AD pathogenesis and served as platforms for AD drug research. Experiments demonstrated that both Aβ and pTau might start neurodegenerative processes and are necessary for cognitive decline. The two pathologies act in synergy. Inhibition of the formation of toxic Aβ and pTau aggregates has been an old drug target. Recently, successful Aβ clearance by monoclonal antibodies has raised new hopes for AD treatments if the disease is detected at early stages. More recently, novel targets, e.g., improvements in amyloid clearance from the brain, application of small heat shock proteins (Hsps), modulation of chronic neuroinflammation by different receptor ligands, modulation of microglial phagocytosis, and increase in myelination have been revealed in AD research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Chemistry, University of Szeged, Dóm Square 8, H-6720 Szeged, Hungary.
- ELKH-SZTE Biomimetic Systems Research Group, Eötvös Loránd Research Network (ELKH), Dóm Square 8, H-6720 Szeged, Hungary.
ORCID-Profile: Ferenc Bogár
Förderung
- National Research, Development and Innovation Office
- National Research Development and Innovation Office (NKFIH)
Zitieren
APA
Penke, B., Szűcs, M., & Bogár, F. (2023). New Pathways Identify Novel Drug Targets for the Prevention and Treatment of Alzheimer’s Disease. International Journal of Molecular Sciences, 24(6), 5383. https://doi.org/10.3390/ijms24065383
Vancouver
Penke B, Szűcs M, Bogár F. New Pathways Identify Novel Drug Targets for the Prevention and Treatment of Alzheimer’s Disease. International Journal of Molecular Sciences. 2023;24(6):5383. doi:10.3390/ijms24065383
BibTeX
@article{Penke2023,
author = {Penke, Botond and Szűcs, Mária and Bogár, Ferenc},
title = {New Pathways Identify Novel Drug Targets for the Prevention and Treatment of Alzheimer’s Disease},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {6},
pages = {5383},
doi = {10.3390/ijms24065383}
}
EUVIMED